

## Charles E. Wentworth III

51 White Oak Court, Wakefield, RI 02879  
(401) 284-0821 office, (401) 226-3688 cell;  
[acschuck@cox.net](mailto:acschuck@cox.net); [wentworth@riskmr.com](mailto:wentworth@riskmr.com)

### Professional experience

---

#### **Partner, Risk Management Resources LLC (2004 - Present)**

- Principal role in database development, technical/analytic plan writing, data analysis, and graphical creations
- Databases warehoused and analyzed: General Practice Research Database (GPRD), The Health Improvement Network database (THIN), Pharmetrics, clinical databases

#### **Principal, Analytic Consulting Solutions, Inc. (2000 - Present)**

- Principal role in all database development, statistical analyses, and graphical creations
- Works in team effort with client scientists to show/describe analytic details and develop analytic plans
- Designs detailed analytic plans with collaborating client to outline project deadlines and manage analytic tasks
- Databases developed, investigated, and analyzed: GPRD, THIN, clinical trial data, large insurance claims databases (Pharmetrics, UHC/Ingenix, BCBS), physician practice databases, NHANES, Medicaid, FDA adverse event reporting system data, pharmacy transaction data, case report form data
- Areas of research: respiratory, arthritis, HIV, antibiotics, diabetes, allergic rhinitis, cancer
- Conducted epidemiologic/safety analyses of a multi-center trial database and prepared graphics/slides for FDA Advisory Committee meeting for the approval of a new respiratory drug
- Designs episodes of therapy to derive epidemiologic differences in utilization, cost of care, and discontinuation / switching patterns
- Perform survival analysis and logistic/poisson regression to compare treatment groups by multiple outcomes
- Clients: Amgen, Blue Cross Blue Shield Association, Boehringer-Ingelheim Pharmaceuticals, EPIC, Glaxo-SmithKline, i3 (Ingenix), Joel Hay Consulting, Merck & Co. Inc., Pharmacia Corporation, University of Southern California, University of Washington

#### **Senior Director R&D, Quintiles Transnational – Bioinformatics division (1998 –2001)**

- Developed models and processes for the Rx Market Monitor®, Rx Dosage Insight®, Pharmacy Cost Analyzer®, and MDProfiler® (OLAP) tool which queries in-house real-time pharmacy transaction data used for pharmaceutical market-research analyses
- Managed analytic team conducting custom studies using the nation’s largest real-time pharmacy transaction database
- Managed process to update data each week at Web data-hosting site Perot Systems based in Dallas
- Co-inventor of patented application “System and method for analyzing de-identified health care data”

#### **Lead Analyst, Epidemiology Resources Inc. (1995 –1998)**

- Analyzed United Health Care claims database to address the safety of new leukotriene receptor antagonist
- Designed and created relational database of pooled multi-national clinical trial database to demonstrate the effectiveness of new asthma therapy
- Analyzed in-house health plan claims database to evaluate the cost-effectiveness of medications and assess the safety of medications based on medical event rates

\* Member International Society Pharmacoepidemiology (ISPE)

### Education

---

#### **PhD Candidate, Pharmacoepidemiology**

*University of Rhode Island, Kingston, Rhode Island*

#### **MS Degree, Statistics**

*University of Rhode Island, Kingston, Rhode Island (August 1996)*

- Thesis: *Estimating Spatially Clumped Individuals Using Adaptive Cluster Sampling*
- Received full assistantship for teaching and research

#### **BS Degree, Mathematics Education and Applied Statistics (minor)**

*Boston University, Boston, Massachusetts (May 1993)*

**New England Epidemiology Institute**, summers 1996-98

## **Computer Software / Applications**

---

SAS, Stata, Oracle, Foxpro, Sybase, StatView, Access, Excel, PowerPoint

## **Publications**

---

Thomas A. Burke, Miriam C. Sturkenboom, Pamela A. Ohman-Strickland, **Charles E. Wentworth**, George G. Rhoads. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. *Pharmacoepidemiology and Drug Safety*. Published Online: 2 Jul 2007

Jara M, Lanes S, **Wentworth C**, May C, Kesten S. Comparative Safety of Long-Acting Inhaled Bronchodilators. *Drug Safety*, 2007; 30 (12): 1151-1160.

Arellano FM, **Wentworth C**, Arana A, Fernandez C, Paul C. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. *Journal of Investigative Dermatology*, 2007; 127, 808-816.

Keston S, Jara M, **Wentworth C**, Lanes S. Pooled Clinical Trial Analysis of Tiotropium Safety. *Chest*, 2006; 130:1695-1703

Arellano FM, Yood M, **Wentworth C**, Oliveria S, Rivero E, Verma A, Rothman K. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAID) in UK and USA populations. Implications for COX-2 cardiovascular profile. *Pharmacoepidemiology and Drug Safety* 2006; 15: 861-872

Burke TA, Sturkenboom MC, Lu S, **Wentworth CE**, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. *J Hypertens* 2006; 24:1193–1200.

Zhao SZ, **Wentworth C**, Burke TA, Makuch RW. Drug Switching Patterns Among Patients With Rheumatoid Arthritis and Osteoarthritis Using COX-2 Specific Inhibitors and Non Specific NSAIDs. *Pharmacoepidemiology and Drug Safety* 2004, 13(5):277-287

Rothman KJ, **CE Wentworth**. Mortality of cystic fibrosis patients receiving tobramycin solution for inhalation. *Epidemiology* 2003, 14(1):55-59

Osterhaus, J, C May, T Burke, **CE Wentworth**. Physician-reported management of edema and destabilized blood pressure in COX-2 specific inhibitor users with OA and treated hypertension. *Clinical Therapeutics*, 2002; volume 24, number 6 (969-989)

Johnson ES, SF Lanes, **CE Wentworth**, MH Satterfield, BL Abebe, LW Dicker. A metaregression analysis of the dose-response effect of aspirin on stroke. *Archives of Internal Medicine*, 1999; 159:1248-1253

Lanes SF, JE Garrett, **CE Wentworth**, JM Fitzgerald, JP Karpel. The effect of adding nebulized ipratropium bromide to salbutamol (albuterol) in the treatment of acute asthma: a pooled analysis of three trials. *Chest*, 1998; 114:365-372

Lanes SF, LL Lanza, **CE Wentworth**. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. *American Journal of Respiratory and Critical Care Medicine*, 1998; 158:857-861

Zhao SZ, **Wentworth C**, Burke TA, Makuch RW. Duration of Treatment with Celecoxib, Rofecoxib, and Non-Specific NSAIDs Among Managed Care Enrollees with Rheumatoid Arthritis and Osteoarthritis: A Measure of Comparative Drug Effectiveness. *Value in Health*, submitted.

Zhao SZ, **Wentworth C**, Makuch RW. Re-Initiation of NSAIDs and COX-2 Specific Inhibitors Following Treatment Discontinuation Among Arthritis Patients in a US Managed Care Organization. *Journal of General Internal Medicine*, submitted.